Emergent BioSolutions (NYSE:EBS) Trading Down 4%

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) dropped 4% during trading on Friday . The stock traded as low as $10.03 and last traded at $10.09. Approximately 46,501 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,547,108 shares. The stock had previously closed at $10.51.

Wall Street Analyst Weigh In

EBS has been the subject of several research reports. JPMorgan Chase & Co. restated an “underweight” rating and issued a $9.00 price objective (down from $23.00) on shares of Emergent BioSolutions in a report on Friday, March 17th. Benchmark upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Monday, April 10th. StockNews.com assumed coverage on shares of Emergent BioSolutions in a report on Thursday, March 16th. They issued a “sell” rating for the company. Finally, TheStreet downgraded shares of Emergent BioSolutions from a “c-” rating to a “d” rating in a research report on Monday, February 27th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Emergent BioSolutions has an average rating of “Hold” and a consensus target price of $28.00.

Emergent BioSolutions Stock Down 12.7 %

The stock’s 50-day moving average price is $9.84 and its two-hundred day moving average price is $12.31. The stock has a market capitalization of $463.11 million, a PE ratio of -1.14 and a beta of 0.93. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.70 and a current ratio of 0.98.

Emergent BioSolutions (NYSE:EBS – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50). Emergent BioSolutions had a negative net margin of 19.97% and a negative return on equity of 7.57%. The firm had revenue of $165.10 million for the quarter, compared to analysts’ expectations of $142.85 million. During the same period last year, the company posted $0.18 earnings per share. The business’s revenue for the quarter was down 46.3% compared to the same quarter last year. As a group, analysts expect that Emergent BioSolutions Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Emergent BioSolutions

A number of institutional investors have recently made changes to their positions in EBS. Gladius Capital Management LP boosted its holdings in shares of Emergent BioSolutions by 96.8% during the 4th quarter. Gladius Capital Management LP now owns 3,113 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,531 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Emergent BioSolutions during the 4th quarter valued at about $56,000. Covestor Ltd boosted its holdings in shares of Emergent BioSolutions by 43.8% during the 1st quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 491 shares during the last quarter. Ancora Advisors LLC bought a new position in shares of Emergent BioSolutions in the 1st quarter worth approximately $66,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Emergent BioSolutions in the first quarter worth approximately $69,000. Hedge funds and other institutional investors own 80.44% of the company’s stock.

About Emergent BioSolutions

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.